MedTrace Logo

Cerebrovascular Reactivity in Alzheimer's Disease

NCT03650816 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2024-06-24

No results posted yet for this study

Summary

The etiology of Alzheimer's disease (AD), the most common type of dementia, remains largely undefined and the early diagnostic and effective treatments are still not available. In addition to the neuropathological hallmarks, cerebrovascular dysfunction has been identified as an important component of AD. Using the experimental models, we showed that cerebrovascular reactivity (CVR), the ability of cerebral vessels to dilate or constrict in response to stimuli, is impaired very early in AD. We designed this trial to compare CVR to carbon dioxide (CVR CO2) in AD patients and in persons with subjective cognitive impairment (SCI), the cognitively healthy individuals which began to worry about worsening their memory, and to correlate CVR CO2 with AD markers in cerebrospinal fluid and the blood markers of endothelial function. We hypothesize that CVR represents a potential diagnostic/prognostic marker and an attractive target for the development of new therapeutics in AD.

Conditions

  • Alzheimer Disease
  • Subjective Cognitive Impairment

Interventions

OTHER

Doppler ultrasonography

Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.

OTHER

Biospecimen collection

Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity

Sponsors & Collaborators

  • Fondation Plan Alzheimer

    collaborator OTHER

  • Naturalia & Biologia

    collaborator UNKNOWN

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Florence FAVREL-FEUILLADE · Clinical Research and Innovation Delegation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2023-02-15
Completion
2023-02-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03650816 on ClinicalTrials.gov